Navigation Links
FDA approves ABILIFY(R) (aripiprazole) as the first medication for add-on treatment of MDD
Date:11/20/2007

ts, the rate of discontinuation due to adverse reactions with the use of adjunctive ABILIFY compared to placebo plus ADT was 6 percent vs 2 percent, respectively. The most commonly observed adverse reactions (incidence greater than or equal to 5 percent and at least twice the incidence of placebo plus ADT) associated with the use of adjunctive ABILIFY were akathisia (25 percent vs 4 percent), restlessness (12 percent vs 2 percent), insomnia (8 percent vs 2 percent), constipation (5 percent vs 2 percent), fatigue (8 percent vs 4 percent) and blurred vision (6 percent vs 1 percent).

About Major Depressive Disorder

Major depressive disorder is a serious mental illness(4) characterized by one or more major depressive episodes.(5) Depression affects approximately 13 to 14 million adults,(2) or about 6.7 percent of the adult population in a given year,(6) and is one of the most common mental health disorders.(7) Depression is one of the leading causes of disability in the U.S.(8) In 2000, the total economic burden of treating depression in the U.S. was $83.1 billion, with workplace costs, including missed days and lack of productivity due to illness, accounting for the majority of the total economic burden (62 percent).(9) Other economic burdens in 2000 included $26.1 billion (31 percent) for treatment costs and $5.4 billion (7 percent) for suicide-related costs.(9)

About ABILIFY (aripiprazole)

The first and only available dopamine partial agonist, ABILIFY is indicated as adjunctive treatment to antidepressant therapy in adults with major depressive disorder.

Initially approved in November 2002, over 12.5 million prescriptions have been written for ABILIFY in the U.S.(10) through June 2007.

ABILIFY is available by prescription only. ABILIFY Tablets should be taken once daily with or without food and are available in 2 mg, 5 mg, 10 mg, 15 mg, 20 mg and 30 mg strengths. As adjunctive treatment to antid
'/>"/>

Contact: David M. Rosen
david.m.rosen@bms.com
609-252-5675
Bristol-Myers Squibb
Source:Eurekalert

0

GOOD

Page: 1 2 3 4 5

Related medicine news :

1. FDA Approves First Anti-Psychotic for Kids
2. FDA Approves New Roche West Nile Virus Blood Screening Test
3. FDA Approves Osteoporosis Drug to Cut Breast Cancer Risk
4. FDA Approves LEVAQUIN(R) Short-Course Therapy for Treatment of Complicated Urinary Tract Infections and Acute Pyelonephritis
5. FDA Approves SOMA(R) (carisoprodol) 250 mg
6. FDA Approves Expanded Label for FluMist(R) to Include Children Two to Five Years of Age
7. FDA approves expanded label for FluMist (influenza virus vaccine live, intranasal) to include childr
8. FDA Approves Expanded Labeling for Campath(R) to Include First-line Treatment for Leading Form of Adult Leukemia
9. ABIH Approves Certification Credit for SSPC Training Courses
10. FDA Approves REALIZE(TM) Adjustable Gastric Band for Morbid Obesity
11. FDA Approves New Flu Vaccine
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/19/2013)... of three important studies have been published in the ... the Congress of Neurological Surgeons . The ... , a part of Wolters Kluwer Health . ... artificial neural networks (ANNs) may improve the ability to ... study in the June Neurosurgery supports increased ...
(Date:6/19/2013)... 2013) In early April, senior leaders from medical, ... Connecticut, to discuss one question: how can first responders ... , The preliminary results of this discussion are now ... The Hartford Consensus ," a concept paper published in ... of Trauma and Acute Care Surgery , official ...
(Date:6/19/2013)... Could drugs that block the body,s system for repairing ... to health? As unlikely as it may seem, those ... and breast cancers driven by a mutation in BRCA, ... revealed she carries the mutation. The compounds, termed PARP ... the current edition of Chemical & Engineering News ...
(Date:6/19/2013)... 19, 2013 PREFERRED Therapy Providers, Inc. ... Arizona to offer a new Medicare Advantage Plan ... Paz, Yavapai and Mohave, Arizona counties. The agreement takes ... effective January 1, 2013 and Maricopa and Pima counties ... Inc., the parent company of WellCare of Arizona has ...
(Date:6/19/2013)... Kansas City will host its first Ciclovia event on Sept. ... section of Main Street in the midtown area will be restricted ... The Main Street Corridor Development and BikeWalkKC ... join the ranks of dozens of cities across the US and ... vibrancy and active lifestyles. , “Ciclovia is the perfect event for ...
Breaking Medicine News(10 mins):Health News:Neurosurgery publishes findings of 3 important studies in June issue 2Health News:Neurosurgery publishes findings of 3 important studies in June issue 3Health News:Hartford consensus aims to improve survival after mass shootings 2Health News:PREFERRED Therapy Providers, Inc. and WellCare of Arizona Finalize Their Agreement to Offer Medicare Advantage Plan to PREFERRED's Arizona Provider Network 2Health News:Main Street Corridor Development Corporation and BikeWalkKC Partner to Host Main Street Day and Kansas City’s First Ciclovia 2Health News:Main Street Corridor Development Corporation and BikeWalkKC Partner to Host Main Street Day and Kansas City’s First Ciclovia 3
... shows , , THURSDAY, Sept. 13 (HealthDay News) -- The HIV ... of sexual partners, U.S. researchers report. , More than half ... 2005 were among gay men, a team at the University ... in five gay men living in cities may be HIV-positive. ...
... Clinic,s,Multidisciplinary Simulation Center is now one of 11 ... be accredited by,the American College of Surgeons (ACS). ... advance medical education that will improve patient,safety by ... pace with,rapidly changing technologies. Mayo,s 10,000-square-foot, state-of-the-art ...
... Drug Control Policy to Include Meth Project ... of New Anti-Methamphetamine Initiative, PALO ALTO, Calif., Sept. 13 ... have been,selected by the White House Office of National Drug ... campaign. The Anti-Meth Campaign was unveiled today by ONDCP ...
... Lowering Kevin Everett,s body temperature helped protect his spinal ... -- As Buffalo Bills football player Kevin Everett was ... with a life-threatening spinal cord injury, he was already ... paralysis. , Everett,s spinal cord was damaged in his ...
... been named,mid-Atlantic region sales executive for AllOne Health ... their employees to take,greater control over their health ... employers alike. (Photo: http://www.newscom.com/cgi-bin/prnh/20070912/NEW120 ) ... Nicholas Hanchak, M.D.,Decker joins the team being headed ...
... Ensure Company Data Safe, Provide Alternate Operations ... Facility in Case ... largest,provider of business services to orthodontic and dental practices,worldwide, has ... Texas, as part of the company,s efforts to strengthen its,infrastructure ...
Cached Medicine News:Health News:Number of Partners Doesn't Explain Gay HIV Rate 2Health News:Number of Partners Doesn't Explain Gay HIV Rate 3Health News:Mayo Clinic Multidisciplinary Simulation Center Receives Distinction as an ACS-Accredited Education Institute 2Health News:Mayo Clinic Multidisciplinary Simulation Center Receives Distinction as an ACS-Accredited Education Institute 3Health News:Meth Project Advertisements Selected for National Prevention Campaign 2Health News:Meth Project Advertisements Selected for National Prevention Campaign 3Health News:Novel Cooling Therapy May Have Aided Injured Football Player 2Health News:Novel Cooling Therapy May Have Aided Injured Football Player 3Health News:Novel Cooling Therapy May Have Aided Injured Football Player 4Health News:Frances Decker Named Mid-Atlantic Region Sales Executive for AllOne Health Management Solutions 2Health News:OrthoSynetics(TM) Opens New Data Center, Colocation Facility 2
(Date:6/19/2013)... MUMBAI, India , June 19, ... Book Bureau has recently added DrugPatentWatch ... Databases. ( http://www.bharatbook.com/drugpatentwatch-tour.pdf ) ... DrugPatentWatch provides comprehensive information on pharmaceutical, ... value-added information supports the critical business ...
(Date:6/19/2013)... --  Nektar Therapeutics (Nasdaq: NKTR ) today ... study for NKTR-181, a first-in-class, opioid analgesic molecule ... slow rate of entry is designed to reduce the euphoria ... current opioid analgesics. 1 In the study data being ... in "drug liking" and "feeling high" scores and had highly ...
(Date:6/19/2013)... June 19, 2013 BD Biosciences, a segment of ... a leading global medical technology company, today announced the launch ... latest in its line of high-performance research flow cytometers. ... multicolor analysis with the most compact footprint in its class ... a height of 30" (76.2 cm). Recognizing that space is ...
Breaking Medicine Technology:Drug Patent Watch 2Drug Patent Watch 3Nektar Therapeutics Presents Positive Data from Human Abuse Liability Study for NKTR-181, a First-in-Class Investigational Opioid to Treat Chronic Pain, at 2013 Annual Meeting of The College on Problems of Drug Dependence 2Nektar Therapeutics Presents Positive Data from Human Abuse Liability Study for NKTR-181, a First-in-Class Investigational Opioid to Treat Chronic Pain, at 2013 Annual Meeting of The College on Problems of Drug Dependence 3Nektar Therapeutics Presents Positive Data from Human Abuse Liability Study for NKTR-181, a First-in-Class Investigational Opioid to Treat Chronic Pain, at 2013 Annual Meeting of The College on Problems of Drug Dependence 4Nektar Therapeutics Presents Positive Data from Human Abuse Liability Study for NKTR-181, a First-in-Class Investigational Opioid to Treat Chronic Pain, at 2013 Annual Meeting of The College on Problems of Drug Dependence 5Nektar Therapeutics Presents Positive Data from Human Abuse Liability Study for NKTR-181, a First-in-Class Investigational Opioid to Treat Chronic Pain, at 2013 Annual Meeting of The College on Problems of Drug Dependence 6Nektar Therapeutics Presents Positive Data from Human Abuse Liability Study for NKTR-181, a First-in-Class Investigational Opioid to Treat Chronic Pain, at 2013 Annual Meeting of The College on Problems of Drug Dependence 7Nektar Therapeutics Presents Positive Data from Human Abuse Liability Study for NKTR-181, a First-in-Class Investigational Opioid to Treat Chronic Pain, at 2013 Annual Meeting of The College on Problems of Drug Dependence 8Nektar Therapeutics Presents Positive Data from Human Abuse Liability Study for NKTR-181, a First-in-Class Investigational Opioid to Treat Chronic Pain, at 2013 Annual Meeting of The College on Problems of Drug Dependence 9New BD Biosciences Flow Cytometry Cell Analyzer Enables Complex Multicolor Experiments in Disease Research 2
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
Medicine Products: